Q2 2013 Earnings Call (Transcript)

Discussion in 'Amgen IT' started by quickann, Jul 31, 2013 at 3:12 AM.

Tags: Add Tags
  1. quickann

    quickann Guest

    Some quotes from the transcript
    "I'd like to review our Q2 performance on our portfolio starting with Enbrel. Enbrel continues to be recognized by rheumatologists and dermatologists with its track record of efficacy, safety and long term experience. We're committed to invest in Enbrel long term. In quarter two, Enbrel's sales grew 9% year-over-year primarily due to price."

    "We actually saw penetration levels increase in quarter two. NEUPOGEN sales were down 2% year-over-year. Declines in unit demand in the U.S. And the rest of the world were partially offset by price and the impact of Medicaid adjustment. EPOGEN was up 15% quarter-over-quarter due to increased unit demand as a result of the peginesatide recall, as well as the impact of Medicaid adjustment. We continue to work with the dialysis link to ensure uninterrupted supply for dialysis patients. Aranesp Global sales were up 12% quarter-over-quarter and were flat excluding impact for Medicaid adjustments."

    http://www.earningsimpact.com/Transcript/82349/AMGN/Q2-2013-Earnings-Call